高血压合并糖尿病患者52例临床治疗分析

52 Patients with High Blood Pressure, Diabetes Mellitus Clinical Analysis

目的分析苯磺酸左旋氨氯地平联合厄贝沙坦对高血压合并糖尿病的治疗效果。方法该研究选取2012年7月—2014年6月52例高血压合并糖尿病患者为对象,随机分成两组。对照组患者接受苯磺酸左旋氨氯地平片治疗,实验组患者接受苯磺酸左旋氨氯地平联合厄贝沙坦治疗。连续用药12周,对比分析两组患者治疗前后收缩压(SBP)、舒张压(DBP)、胰岛素抵抗指数(HOMA-IR)的变化和不良反应的差异。结果采用t检验分析进行数据统计,治疗后患者SBP、DBP、HOMAIR均明显下降,其中实验组各指标下降幅度明显大于对照组,差异有统计学意义(P<0.05)。采用χ2检验分析进行数据统计,两组治疗期间不良反应发生率差异无统计学意义(P>0.05)。结论采用苯磺酸左旋氨氯地平联合厄贝沙坦治疗高血压合并糖尿病,可有效控制血压,改善胰岛素抵抗,将其作为高血压合并糖尿病治疗的有效方案推广应用。

Objective To analyze the acid Levamlodipine irbesartan on hypertension and diabetes treatment. Methods This study selected 52 cases of hypertension and diabetes patients from July 2012 to June 2014 as objects, were randomly divided into two groups. The control group of patients receiving acid L-amlodipine treatment, the experimental group received acid Levamlodipine irbesartan treatment. Continuous medication for 12 weeks, the two groups were analyzed before and after treatment systolic blood pressurd （SBP）, diastolic blood pressure difference （DBP）, insulin resistance index （HOMA-IR） changes and adverse reactions. Results Using the t test for statistical analysis, after treatment SBP, DBP, HOMA-IR were significantly decreased in the experi- mental group, the index decline was significantly higher than the control group, the difference was statistically significant （P〈0.05）. Chi-square test for statistical analysis, the two groups during treatment incidence of adverse reactions was no significant difference （P〉 0.05）. Conclusion Acid Levamlodipine irbesartan treatment of hypertension and diabetes, which can effectively control blood pressure, improve insulin resistance, hypertension and diabetes as a treatment an effective program application.